Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges
Michail Kokkorakis(Harvard University), Christos S. Mantzoros(Beth Israel Deaconess Medical Center), Vasilios Kotsis(Aristotle University of Thessaloniki), Rohit Loomba(University of California San Diego), Arun J. Sanyal(Virginia Commonwealth University), Michael A. Hill(University of Missouri), Chrysoula Boutari(Aristotle University of Thessaloniki)
Cited by 138
Related Papers
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
|Hepatology|2017|7.2k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Role of leptin in the neuroendocrine response to fasting
|Nature|1996|3.1k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k